Labopharm Inc: Premium Company Profile

Publication Date	December 2007
Publisher	Datamonitor
Product Type	Databook
Pages	55
ISBN Number	not applicable
Product Code	DAT09425

Price

£265.00
approximately: $458 | €336

PRINT £265 ($458 | €336)

Order above formats by FAX

Summary

Introduction

Labopharm, formerly known as Centre de Recherche Appliquee Pharmaceutique (CRAP), is a specialty pharmaceutical company optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies: Contramid and PNDS. . It is currently focusing on developing and commercializing its lead product candidate, Trazodone for the potential treatment of depression.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Labopharm's primary focus is developing small molecule drugs for two therapeutic indications, pain and depression. The company currently has one marketed product, Tramadol, indicated for moderate to severe pain, in Europe and Canada through its marketing partners. Trazodone, indicated for depression is currently in Phase III clinical development.

The company's total revenues increased at a CAGR of 102.9% during 2002-2006, from $0.8 million to $14 million. This represents an absolute total growth of +$13.1 million for total revenues during the same period. License, collaboration and other revenues are a major contributor to revenue growth by contributing +$7.1 million.

The company's biggest contributor to sales growth out to 2010 again will be revenues from license, collaboration and other. Revenues from license, collaboration and other are expected to increase from $8 million in 2006 to $75 million in 2010, recording an absolute growth of +$67 million.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Overview
Catalyst
- Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Locations and Subsidiaries
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Business Segment Performance
- Geographic Segment Performance
- Products & Services
- Marketed Products
- Pipeline Products
- Historical Product Sales
- AC Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Discovery and Product Development
- Sales
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask the analyst
- Datamonitor consulting
- Disclaimer
- Figure 1: Labopharm - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: Labopharm - Key Strategic Revenues, 2002-2006 ($ Mn)
- Figure 3: Labopharm - Key Strategic Revenues, 2006-2010 ($ Mn)
- Table 1: Labopharm - Key Facts
- Table 2: Labopharm - Locations and Subsidiaries
- Table 3: Labopharm - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 4: Labopharm - Key Events Impacting Share Price Performance
- Table 5: Labopharm - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 6: Labopharm - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
- Table 7: Labopharm - Balance Sheet, 2002-2006 ($ Mn)
- Table 8: Labopharm - Cash Flow, 2002-2006 ($ Mn)
- Table 9: Labopharm - Revenue Breakdown by Division, 2002-2006 ($ Mn)
- Table 10: Labopharm - Geographic Breakdown, 2002-2006 ($ Mn)
- Table 11: Labopharm - Marketed Products
- Table 12: Labopharm - in-house Pipeline Products
- Table 13: Labopharm - Collaboration Products
- Table 14: Labopharm - Product Sales, 2002-2006 ($ Mn)
- Table 15: Labopharm - Forecast Sales, 2006-2010 ($ Mn)
- Table 16: Labopharm - Key Competitors
- Table 17: Labopharm - Key Suppliers
- Table 18: Labopharm - Key Clients
- Table 19: Labopharm - Key Shareholders
- Table 20: Labopharm - SWOT Analysis Summary
- Table 21: Labopharm - Value Chain Analysis
- Table 22: Labopharm - Scorecard
- Table 23: Labopharm - Key Employees
- Table 24: Labopharm - Financial and Operational Overview